Rubitecan: Phase II data; Phase III
SUPG reported data from a Phase II trial of rubitecan in 58 pancreatic cancer patients who failed prior treatments. Of the 45 patients with measurable disease, 4 had partial responses (>50 percent tumor reduction) and 11 had stable disease. Median survival for the 4 patients with partial responses was 1 year, with 2 patients alive for >20 months, and median survival for the 11 patients with stable disease was 8 months, with 3 patients alive for >1 year.
In a Phase I trial of 13 patients with refractory tumors, the combination of rubitecan and Eli Lilly's Gemzar gemcitabine produced tumor responses in 2 patients and stable disease in another 2 patients. And in another Phase I trial of 9 patients with refractory tumors, the combination of rubitecan and cisplatin produced a full remission in 1 patient and a partial remission in another. ...